Home › Trials › NCT06491056
Clinical trial Recruiting at 1 site Observational Ages 40 to 85 Men only

Observational study on focal therapy for prostate cancer in Asia

Official title: Prospective Multicenter Asian Observational Study of Oncological and Functional Outcomes After Focal Therapy of Prostate Cancer

Run by Singapore General Hospital · NCT06491056 · Data updated 2026-11-12

This study looks at how well different focal therapy treatments for prostate cancer work and how safe they are for patients in Asia with localized disease.

More Prostate Cancer trials

Quick facts

Study typeObservational
Ages40 Years to 85 Years
SexMen only
Enrollment500 (estimated)
SponsorSingapore General Hospital
Academic / other
Locations1 site (Singapore)
StatusRecruiting
StartedMay 6, 2023
Main results expectedMay 6, 2028
Study endsMay 6, 2048
Registry record updatedJuly 8, 2024
Trial IDNCT06491056 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are men diagnosed with prostate adenocarcinoma who meet specific criteria regarding Gleason score, cancer volume, PSA levels, and clinical stage.

Probably not a fit

Patients with extra-prostatic extension of cancer or those who do not meet the inclusion criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study focuses on patients with prostate cancer undergoing various focal therapy techniques, including cryotherapy, high intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and focal laser ablation. The study aims to gather data on the effectiveness and safety of these partial gland ablation methods in treating prostate adenocarcinoma. Patients will be recruited from multiple centers across Asia, specifically targeting those with localized disease and specific eligibility criteria.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of focal therapies, potentially leading to improved treatment options for prostate cancer patients.

How similar studies have gone: Other studies have explored focal therapies for prostate cancer, showing promising results, but this particular study's multicenter approach in Asia may provide novel insights.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Prostate Adenocarcinoma
* Maximum Gleason score 4+4
* Maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion)
* Maximum Prostate Specific Antigen (PSA) level 15 ng/dl
* Maximum clinical stage T2c
* American Society of Anesthesiologist Criteria 2 or less

Exclusion Criteria:

* Extra-prostatic Extension on multi parametric magnetic resonance imaging (mpMRI); capsular contact is permitted

Where it's running

  • Singapore General Hospital
    Singapore, Singapore     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Singapore General Hospital 29
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.